Merck: 'Strong Buy' Lipfendra FDA First And Continued Oncology Expansions
Strong Buy on oncology pipeline gains and LIPFENDRA launch, with KEYTRUDA patent risks. Click for this MRK update.
Dr. Crandall: New Cholesterol Pill a 'Game Changer'
A newly approved cholesterol-lowering pill could offer millions of people a more convenient way to dramatically reduce "bad" LDL cholesterol, especially those who can't tolerate statins or whose ...
Fierce Pharma
Fierce Pharma Asia—GSK, Merck ADCs’ trial wins; AZ’s $1.5B EGFR buy; Biotechs’ new patent tricks
Antibody-drug conjugates from Kelun-Biotech and Hansoh Pharma, respectively partnered with Merck & Co. and GSK, delivered ...
FDA approves first daily pill to drastically lower cholesterol levels
Federal regulators approved a first-of-its-kind cholesterol medication from Merck that rivals the effectiveness of powerful ...
Merck stock rises after US approval for powerful cholesterol-cutting pill
It’s the first pill that lowers blood cholesterol far better than statins, medicines that a quarter of adults take to reduce ...
FDA approves a first-of-its-kind pill to cut cholesterol in high-risk patients
The Food and Drug Administration has approved a first-of-its-kind pill that can drastically reduce cholesterol in a way that’s previously only been available with expensive, injectable drugs. The drug ...
Cholesterol pill approved by FDA, billed as first of its kind, similar to injectable drugs
The Food and Drug Administration approved a first-of-its-kind pill that can reduce cholesterol in a way that’s previously ...
FDA approves new kind of cholesterol pill
Merck’s pill, called Lipfendra, is a PCSK9 inhibitor, which works in a different way from a statin to lower cholesterol.
BioPharma Dive
Merck wins first approval of a PCSK9 cholesterol pill
The speedy clearance of Lipfendra is an important milestone for Merck and the result of a controversial voucher program put in place by former FDA commissioner Marty Makary.